319 related articles for article (PubMed ID: 23406628)
1. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
3. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
4. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
6. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
7. Engineered antibody Fc variants with enhanced effector function.
Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
[TBL] [Abstract][Full Text] [Related]
8. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
9. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
10. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
[TBL] [Abstract][Full Text] [Related]
11. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
12. Fc-engineered antibodies with immune effector functions completely abolished.
Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
[TBL] [Abstract][Full Text] [Related]
13. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.
Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G
AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934
[TBL] [Abstract][Full Text] [Related]
14. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
15. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
[TBL] [Abstract][Full Text] [Related]
16. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).
Mimoto F; Katada H; Kadono S; Igawa T; Kuramochi T; Muraoka M; Wada Y; Haraya K; Miyazaki T; Hattori K
Protein Eng Des Sel; 2013 Oct; 26(10):589-98. PubMed ID: 23744091
[TBL] [Abstract][Full Text] [Related]
17. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
18. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
19. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
20. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
